Press kit for announcement by Alloplex of 30 October, 2024: Breakthrough Cancer Trial: retraining immune cells offers new hope for cancer patients.
SUPLEXA manufacturing process
Alloplex CEO Dr. Borriello discusses how Alloplex was founded and touches on the SUPLEXA concept.
Embed Code:
.jpg(color)
.png(color)
.svg(color)
.jpg(color)
.png(color)
.svg(color)
.jpg(color)
.png(color)
.svg(color)
.jpg (1.8MB)
.jpg (2MB)
.jpg (2.7MB)<div style="padding:56.25% 0 0 0;position:relative;"><iframe src="https://player.vimeo.com/video/928229379?h=894ad18f5a&badge=0&autopause=0&player_id=0&app_id=58479" frameborder="0" allow="autoplay; fullscreen; picture-in-picture; clipboard-write" style="position:absolute;top:0;left:0;width:100%;height:100%;" title="SUPLEXA: a novel approach to Immuno-Oncology"></iframe></div><script src="https://player.vimeo.com/api/player.js"></script>Embed Code:
<div style="padding:56.25% 0 0 0;position:relative;"><iframe src="https://player.vimeo.com/video/930878705?h=52d39fc858&badge=0&autopause=0&player_id=0&app_id=58479" frameborder="0" allow="autoplay; fullscreen; picture-in-picture; clipboard-write" style="position:absolute;top:0;left:0;width:100%;height:100%;" title="A novel approach to Immuno-Oncology"></iframe></div><script src="https://player.vimeo.com/api/player.js"></script>To request interviews, high res images or other materials, media are asked to:
Email: media@alloplexbio.com
Attn: Lesley White, Alloplex Australia
